CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $32.48 to $32.48
• 50-Day Range: $32.18 to $32.48
• 52-Week Range: $7.26 to $32.50
• Volume: 73 shs
• Average Volume: 4.11 million shs
• Market Capitalization: $3.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBAY Stock Analysis - Frequently Asked Questions

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.42 million.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 4/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CBAY
• CIK: 1042074
• Web: www.cymabay.com
• Phone: (510) 293-8800
• Fax: 510-293-9090
• Employees: 101
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-105,370,000.00
• Net Margins: N/A
• Pretax Margin: -339.11%
• Return on Equity: -50.72%
• Return on Assets: -31.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.96
• Quick Ratio: 10.96

Sales & Book Value

• Annual Sales: $31.07 million
• Price / Sales: 119.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.58 per share
• Price / Book: 12.59

Miscellaneous

• Outstanding Shares: 114,724,000
• Free Float: 106,693,000
• Market Cap: $3.73 billion
• Optionable: Optionable
• Beta: 0.32